<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1404">
  <stage>Registered</stage>
  <submitdate>19/06/2006</submitdate>
  <approvaldate>27/06/2006</approvaldate>
  <actrnumber>ACTRN12606000255583</actrnumber>
  <trial_identification>
    <studytitle>Low dose vitamin E and blood pressure</studytitle>
    <scientifictitle>To investigate if low dose mixed tocopherols and sesame can reduce blood pressure in hypertensive individuals</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Hypertension</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Hypertension</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The study is a randomised, double-blind, placebo controlled trial with a 6 week intervention period. Treatment arms are:
1. 50mg mixed tocopherol supplement + 10g placebo spread
2. Placebo supplement + 10g sesame spread
3. 50mg mixed tocopherol supplement + 10g sesame spread

Capsules will be taken once in the morning and once in the evening as 25mg capsules. 5g of spread will consumed once in the morning and in the evening along with the capsules.</interventions>
    <comparator>4. Placebo supplement + placebo spread</comparator>
    <control>Placebo</control>
    <interventioncode>Lifestyle</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>1. Blood pressure (24hr ambulatory blood pressure monitoring)</outcome>
      <timepoint>Measured at baseline and following 6 weeks intervention</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>2. Serum &amp; cellular tocopherol enrichment</outcome>
      <timepoint>Measured at baseline and following 6 weeks intervention</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>1. Oxidative stress (plasma &amp; urinary F2-isoprostanes)</outcome>
      <timepoint>Measured at baseline and following 6 weeks intervention.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>2. Cytochrome P450 activity </outcome>
      <timepoint>Measured at baseline and following 6 weeks intervention.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>3. Inflammation</outcome>
      <timepoint>Measured at baseline and following 6 weeks intervention.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Hypertensive, either treated or untreated with a systolic blood pressure between 100-160 mmHg and a distolic blood pressure &lt;100 mmHg (mean of 3 readings taken every 2 mins).</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Diabetes requiring medication2. Recent coronary/cerebrovascular event &lt;6 months, or heart failure3. Bdy mass index &gt;354. Use of pure vitamin E supplements5. Use of oral contraceptives or premenopausal6. Evidence of renal impairment7. Smoking8. Alcohol intake &gt;40g/day men or 30g/day women9. Episodic use of non-steroidal anti-inflammatory medication.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Sealed in opaque envelopes</concealment>
    <sequence>Permutated block randomisation using computer generated random numbers in variable blocks</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Pharmacokinetics / pharmacodynamics</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/07/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>80</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Western Australia</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>NH&amp;MRC</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>N/A</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study is designed to look at the effect of supplementation with low dose mixed vitamin E and sesame, either alone on in combination on blood pressure in people who already have elevated blood pressure. The study will be double-blinded with both the study co-ordinator and participants blinded to the tocopherol treatment. However, because of a noticeable taste difference between the placebo spread and the sesame spread, this will not be able to be blinded</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname> School of Medicine &amp; Pharmacology Clinical Trials Unit at Royal Perth Hospital-University of Western Australia Human Research Ethics Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate>13/03/2006</ethicapprovaldate>
      <hrec>RA/4/1/1355</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor Kevin Croft</name>
      <address>School of Medicine and Pharmacology (RPH)
University of Western Australia
Box X2213 GPO 
Perth WA 6847</address>
      <phone>+61 8 92240275</phone>
      <fax>+61 8 92240246</fax>
      <email>kcroft@cyllene.uwa.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Professor Kevin Croft</name>
      <address>School of Medicine and Pharmacology (RPH)
University of Western Australia
Box X2213 GPO 
Perth WA 6847</address>
      <phone>+61 8 92240275</phone>
      <fax>+61 8 92240246</fax>
      <email>kcroft@cyllene.uwa.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>